Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

July 25, 2014 08:00 ET | Source: Galectin Therapeutics Inc.

Galectin Therapeutics to Host Webcast to Discuss Findings From Cohort 2 of Phase 1 Clinical Trial of GR-MD-02 in Fatty Liver Disease With Advanced Fibrosis

NORCROSS, Ga., July 25, 2014 (GLOBE NEWSWIRE) -- Galectin Therapeutics (Nasdaq:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, announced the...
July 22, 2014 08:30 ET | Source: Galectin Therapeutics Inc.

Galectin Therapeutics Announces First Patient Dosed in Cohort 1 of Phase 1B Clinical Trial of GR-MD-02 in Combination with Ipilimumab in Metastatic Melanoma

NORCROSS, Ga., July 22, 2014 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (Nasdaq:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today...
July 09, 2014 08:30 ET | Source: Galectin Therapeutics Inc.

Galectin Therapeutics Added to Russell 2000 Index

NORCROSS, Ga., July 9, 2014 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (Nasdaq:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, announced...
June 23, 2014 08:00 ET | Source: Galectin Therapeutics Inc.

Galectin Therapeutics Announces That Oral Treatment With Galectin-3 Inhibitor GR-MD-02 is Efficacious in Preclinical Model of Fatty Liver Disease With Fibrosis

NORCROSS, Ga., June 23, 2014 (GLOBE NEWSWIRE) -- Galectin Therapeutics (Nasdaq:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, announced today...
May 29, 2014 08:00 ET | Source: Galectin Therapeutics Inc.

Galectin Therapeutics to Present at Jefferies 2014 Global Healthcare Conference

NORCROSS, Ga., May 29, 2014 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (Nasdaq:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today...
May 28, 2014 08:00 ET | Source: Galectin Therapeutics Inc.

Galectin Therapeutics Receives U.S. Patent for GR-MD-02 in Diabetic Nephropathy, a Progressive Kidney Disease

NORCROSS, Ga., May 28, 2014 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (Nasdaq:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today...
May 13, 2014 17:00 ET | Source: Galectin Therapeutics Inc.

Galectin Therapeutics Reports First Quarter 2014 Financial Results

NORCROSS, Ga., May 13, 2014 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (Nasdaq:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today...
May 08, 2014 08:00 ET | Source: Galectin Therapeutics Inc.

Galectin Therapeutics to Hold Conference Call to Provide Corporate Update Following Company's Annual Meeting of Shareholders

ATLANTA, May 8, 2014 (GLOBE NEWSWIRE) -- Galectin Therapeutics (Nasdaq:GALT) will host a conference call at 9:45 A.M. Eastern Time on Wednesday, May 14, 2014, to provide a corporate update following...
April 23, 2014 08:00 ET | Source: Galectin Therapeutics Inc.

Galectin Therapeutics Completes Enrollment of Second Cohort of Phase 1 Trial of GR-MD-02 for NASH (Fatty Liver Disease) With Advanced Fibrosis

NORCROSS, Ga., April 23, 2014 (GLOBE NEWSWIRE) -- Galectin Therapeutics (Nasdaq:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, announced today...
April 17, 2014 10:19 ET | Source: Galectin Therapeutics Inc.

Galectin Therapeutics Announces First Patient Dosed in Second Cohort of Phase 1 Trial of GR-MD-02 for NASH With Advanced Fibrosis

NORCROSS, Ga., April 17, 2014 (GLOBE NEWSWIRE) -- Galectin Therapeutics (Nasdaq:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, announced today...